MENU
NEWS
RESEARCH
CRUKMI logo image CRUKMI logo image

WORLD CLASS BASIC, TRANSLATIONAL AND CLINICAL RESEARCH

PhD STUDENTSHIP - AUTUMN 2024 

Cancer Research UK Manchester Institute

CRUK 4 Year PhD Studentship 2024

We are pleased to announce this exciting postgraduate opportunity within the Leukaemia Immunology and Transplantation research group
Project Title:
"T Cell Responses in Acute Myeloid Leukaemia"
Group Leader:
Application Deadline:
FRIDAY 17 MAY 2024 - 1700 hrs (GMT)
Interview:
MONDAY 17 JUNE 2024, PATERSON NEW BUILDING, WITHINGTON, MANCHESTER, M20 4BX

APPLY

 

Recent advances in cancer immunotherapy have yet to benefit patients with Acute Myeloid Leukaemia (AML), despite allogeneic stem cell transplantation demonstrating the curative potential of leukaemia-reactive T cells. Whilst there is evidence that autologous T-cell responses occur in patients with AML, we do not know whether these are common or robust enough to allow therapeutic manipulation. Overall, the immunology of AML remains understudied and poorly understood. Contributing factors include the complexity of bone marrow, where large numbers of developing, circulating and resting T cells complicate identification of those relevant to disease pathogenesis. Additionally, contemporary approaches such as single-cell sequencing are expensive and generally not powered to identify rare populations that may constitute <1% of T cells.

To address this problem, we developed a T-cell focused mass cytometry panel and analysed ~400m cells from the bone marrow of 160 AML patients, identifying novel T-cell populations associated with AML genotype and clinical outcome. The focus of this PhD project will be the isolation and characterisation of these leukaemia-associated populations. This will involve isolation of rare populations using fresh patient samples, the application of T-cell receptor sequencing to determine clonality, co-culture with autologous leukaemia to establish reactivity and cytotoxic potential, and the use of tissue sections to study localisation and physical association with leukaemia. These results will inform therapeutic strategies to promote anti-tumour immune responses.

We are looking for a hard-working, focused, ambitious person to join our excellent, friendly and interactive team. Our laboratory makes use of a broad range of in vitro and in vivo techniques to study interactions between leukaemia and immune cells, with the aim of developing novel therapies for patients. Our approach spans cutting-edge single cell sequencing and epigenetics, through to murine models, biomarker development and clinical trials.

We would be particularly happy to receive applications from individuals with a strong academic track record and Masters-level and/or other laboratory research experience in leukaemia, cancer biology or immunology.  Applicants should hold or expected to graduate with a first or minimum upper-second class undergraduate honours degree (or equivalent from a non-UK university) as part of a university degree course.  

This project would enable the successful candidate to work in the world-leading research environment of the CRUK Manchester Institute, whilst applying cutting-edge techniques to address a critical clinical problem. Students would gain broad exposure to immunology, haematology, oncology and transplantation. Upon completion, candidates would be well positioned to pursue a career in the fascinating and expanding field of cellular immunotherapy for cancer.

The Cancer Research UK Manchester Institute is proud to be a diverse, open, and global Institute.  Our priority, and that of the University of Manchester, is to support our current students and welcome new ones from Europe and other continents, we therefore encourage students of all nationalities to apply for the programme.  All applications will be considered equally irrespective of ethnicity, disability, sexual orientation, gender, religion/belief, age and nationality.  To help the CRUK Manchester Institute monitor equality, diversity and inclusion, you will be asked to complete and submit an EDI monitoring form during the application process.  Equal opportunities information will not be shared and will not form any part of the selection process or divulged to members of the selecting, recruiting or interview panels.

Successful applicants will receive a non-taxable annual stipend (living allowance) of £21,000 GBP per annum, bench and tuition fees (home and international) covering the full 4 years.  Registration and graduation will be affiliated to the University of Manchester, UK.  PhD University registration entry 1-30 September 2024, PhD Commencement 1 October 2024.

This 4-year PhD studentship will be based at the Cancer Research UK Manchester Institute, New Paterson Building, Withington, Manchester, UK

The CRUK Manchester Institute is located over two adjacent sites; the Oglesby Cancer Research Building, Manchester Cancer Research Centre and our new research facilities in the Paterson Building, Withington, South Manchester next to the The Christie NHS Foundation Trust

 We plan to hold in-person interviews on site; however, we will take into consideration any change in circumstances at the time to ensure the safety of all concerned and in amending the interview format to virtual if deemed appropriate.

Brexit & EU Students

Guidance on the University of Manchester's position on Brexit and how this affects student fee status can be found here.

For further information on your residency and tuition fee status, please visit the following UK CISA page here.

Our funded PhD studentships are inclusive of home/international tuition fees and stipend for the duration of the 4-year programme.  If you are successful and offered a PhD studentship at the Cancer Research UK Manchester Institute, you are not expected to fund any part of the programme.

Informal enquiries should be addressed to the Postgraduate Tutor at: pgt@cruk.manchester.ac.uk.